| Symbol | Company | Owner | Relationship | Date | Transaction | Cost | # Shares | Value ($) | Total Shares | Filing | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RXRX | RECURSION PHARMACEUTICALS, INC. | Najat Khan | Chief R&D Commercial Officer | Aug 15, 2025 | Tax Payment (Shares) | $5.64 | 3,789 | 21,370 | 704,796 | Aug 19, 2025, 06:22 PM | |
| RXRX | RECURSION PHARMACEUTICALS, INC. | Najat Khan | Chief R&D Commercial Officer | Aug 18, 2025 | Sale | $5.52 | 36,599 | 202,173 | 668,197 | Aug 19, 2025, 06:22 PM | |
| RXRX | RECURSION PHARMACEUTICALS, INC. | Najat Khan | Chief R&D Commercial Officer | May 15, 2025 | Tax Payment (Shares) | $4.25 | 3,796 | 16,133 | 708,585 | May 19, 2025, 04:44 PM | |
| RXRX | RECURSION PHARMACEUTICALS, INC. | Najat Khan | Chief R&D Commercial Officer | Feb 03, 2025 | Tax Payment (Shares) | $7.25 | 2,753 | 19,959 | 712,381 | Feb 05, 2025, 04:50 PM |